Non-Hodgkin?s lymphoma (NHL), a cluster of hematological cancers originating from lymphoid tissues is more frequent in developed countries than in the developing world. It is the 10th leading cancer type in Sri Lanka and according to the recent Globacan cancer statistics in Sri Lanka, it has shown 2.9% mortality rate. In such a situation, early diagnosis, and effective monitoring of treatment used in NHL ought to be a huge task to increase the recovery of patients and to reduce mortality rate among them. The absence of a well-recognized system which governs the cell proliferation and survival in NHL baskets developing therapeutic targets. FMS like tyrosine kinase 3 (FLT3)/ligand (FL) system is responsible for the hematopoietic cell proliferation, cell survival and certain intracellular activities that takes place in the normal condition, especially for lymphoid cells. In this review, we study the presence of FLT3 (CD 135) on lymphoid cells in NHL to investigate the possibility of using FLT3/FL system for novel drug targets for NHL.

Non-Hodgkin Lymphoma

FLT3 receptor

FLT3 ligand

Prognosis